PLATELET-ACTIVATING FACTOR AND IT’S INTERRELATION WITH ALLERGIC DISEASES
- Authors: FOMINA DS1, GORYACHKINA LA1, BOBRIKOVA EN1
-
Affiliations:
- Russian Medical Academy of Postgraduate Education
- Issue: Vol 11, No 3 (2014)
- Pages: 22-28
- Section: Articles
- Submitted: 10.03.2020
- Published: 15.12.2014
- URL: https://rusalljournal.ru/raj/article/view/494
- DOI: https://doi.org/10.36691/RJA494
- ID: 494
Cite item
Abstract
Keywords
Full Text
About the authors
D S FOMINA
Russian Medical Academy of Postgraduate Education
Email: daria.s.fomina@gmail.com
Moscow
L A GORYACHKINA
Russian Medical Academy of Postgraduate EducationMoscow
E N BOBRIKOVA
Russian Medical Academy of Postgraduate EducationMoscow
References
- Mullol J. Rupatadine in Allergic Rhinitis and Chronic Urti- caria. Allergy. 2008, v. 63, р. 5-28.
- Quraishi S.A., Davies M.J., Craig T.J. Inflammatory responses in allergic rhinitis: traditional approaches and novel treatment strategies. J. Am. Osteopathol. Assoc. 2004, v. 104, р. 7-15.
- Pearlman D.S. Pathophysiology of the inflammatory response. J. Allergy Clin. Immunol. 1999, v. 104, р. 132-137.
- Bascom R., Pipkorn U., Proud D. et al. Major basic pro- tein and eosinophils-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge: effect of systemic corticosteroids and relationship to eosinophil influx. J. Allergy Clin. Immunol. 1989, v. 84, р. 338-346.
- Bascom R., Pipkorn U., Lichtenstein L.M., Naclerio R.M. The influx of inflammatory cells into nasal washings during the late- phase response to antigen challenge. Effect of systemic steroid pretreatment. Am. Rev. Respir. Dis. 1988, v. 138, р. 406-412.
- Гущин И.С., Курбачева О.М. Аллегия и аллергенспеци- фическая иммунотерапия. М., «Фармарус Принт Медиа». 2010, с. 7.
- Braquet P., Paubert-Braquet, M., Bourgain, R.H. et al. PAF/ cytokine autogenerated feedback networks in microvascular immune injury: consequences in shock, ischemia and graft rejection. J. Lipid. Mediators. 1989, v. 1, р. 75-112.
- Prescott S.M., Zimmerman G.A., Stafforini D.M. Plate- let-activating factor and related lipid mediators TM. Ann. Rev. Biochem. 2000, v. 69, р. 419-445.
- Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Ann. Rev. Pharmacol. Toxicol. 2009, v. 49, р. 123-150.
- Church М., Máspero J., Maurer М., Ryan D. The scope of pharmacological and clinical effects of modern antihistamines, with a special focus on Rupatadine. J. WAO. 2010, v. 3, р. 1-16.
- Shirasaki H., Seki N., Kikuchi M. et al. Expression and localization of platelet-activating factor receptor in human nasal mucosa. Ann. Allergy Asthma Immunol. 2005, v. 95, р. 190-196.
- Brozek J.L., Bousquet J. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines. Revision J. Allergy Clin. Immunol. 2010, v. 126, р. 466-476.
- Stafforini D., Toshio Numao, Tsodikov A. et al. Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. J. Clin. Invest. 1999, v. 103, р. 989-997.
- Kurosawa M., Yamashita T., Kurimoto F. Increased levels of blood platelet-activating factor in bronchial asthmatic patients with active symptoms. Allergy. 1994, v. 49, р. 60-63.
- Kruse S., Mao X.Q., Heinzmann A. et al. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am. J. Hum. Genet. 2000, v. 66, р. 1522-1530.
- Evans D.J., Barnes P.J., Cluzel M., O’Connor B.J. Effects of a potent platelet-activating factor antagonist, SR27417A, on allergen-induced asthmatic responses. American journal of respiratory and critical care medicine. 1997, v. 156, p. 11-16.
- Tamura G., Takishima T., Mue S. et al. Effect of a potent platelet-activating factor antagonist, WEB-2086, on asthma. A multicenter, double-blind placebo-controlled study in Japan. Adv. Exp. Med. Biol. 1996, v. 416, р. 371-380.
- Hozawa S., Haruta Y., Ishioka S., Yamakido M. Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. Am. J. Respir. Crit. Care Med. 1995, v. 152, р. 198-202.
- Hashimoto E.H. Current treatment of severe asthma Clinical & Experimental. Allergy. 2012, v. 42, p. 693-705.
- Кузнецова Т.И. Влияние альдегидогенных и ацильных структурных аналогов фактора активации тромбоцитов на образование супероксидных радикалов лейкоцитами крови человека. Биохимия. 1992, т. 57, № 1, с. 16-20.
- Peter M. Henson. Platelet-activating factor (PAF) as a media- tor of neutrophil-platelet interactions in inflammation. Agents and Actions. 1981, v. 11, p. 545-547.
- Fauler J., Sielhorst G., Frölich J.C. Platelet-activating factor induces the production of leukotrienes by human monocytes. Biochim. Biophys. Acta. 1989, v. 1013, р. 80-85.
- Dahl M.L. Aggregating and prostanoid-releasing effects of platelet-activating factor and leukotrienes on human poly- morphonuclear leukocytes and platelets. Int. Arch. Allergy Appl. Immunol. 1985, v. 76, р. 145-150.
- Izquierdo I., Nieto C., Ramis J. et al. Pharmacokinetics and dose linearity of rupatadine fumarate in healthy volunteers. Exp. Clin. Pharmacol. 1997, v. 19, p. 189.
- Muñoz-Cano R., Valero A., Izquierdo I. et al. Evaluation of nasal symptoms induced by platelet activating factor, after nasal challenge in both healthy and allergic rhinitis subjects pretreated with rupatadine, levocetirizine or placebo in a cross-over study design. Allergy Asthma Clin. Immunol. 2013, v. 9, р. 43.
- Macconi D., Foppolo M., Paris S. et al. PAF mediates neu- trophil adhesion to thrombin or TNF-stimulated endothelial cells under shear stress. Am. J. Physiol. 1995, v. 269, р. 42-47.
- Miyaura S., Eguchi H., Johnston J.M. Effect of a cigarette smoke extract on the metabolism of the proinflammatory autacoid, platelet-activating factor. Circ. Res. 1992, v. 70, р. 341-347.
- Kajiwara N., Sasaki T., Bradding P. et al. Activation of human mast cells through the platelet-activating factor receptor. J. Allergy Clin. Immunol. 2010, v. 125, р. 1137-1145.
- Maurer M., Mager M., Metz M. et al. Revisions to theinterna- tional guidelines on the diagnosis and therapy of chronic urti- caria. Journal der Deutschen Dermatologischen Gesellschaft. 2013, v. 11, p. 971-978.
- Katayama I., Matsui S., Murota H. Platelet activation as a possible indicator of disease activity in chronic urticaria: link with blood coagulation and mast cell degranulatioт. J. Clin. Exp. Dermatol. Res. 2013, v. 4, р. 194-198.
- Krause K., Giménez-Arnau A., Martinez-Escala E. et al. Platelet-activating factor (PAF) induces wheal and flare skin reactions independent of mast cell degranulation. Allergy. 2013, v. 68, р. 256-258.
- Grandel K.E., Farr R.S., Wanderer A.A. et al. Association of platelet-activating factor with primary acquired cold urticaria. N. Engl. J. Med. 1985, v. 313, р. 405-409.
- Takahagi S., Mihara S., Iwamoto K. et al. Coagulation/fibri- nolysis and inflammation markers are associated with disease activity in patients with chronic urticaria. Allergy. 2010, v. 65, р. 649-656.
- Vadas P., Gold M., Perelman B. et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N. Engl. J. Med. 2008, v. 358, р. 28-35.
- Vadas P., Perelman B., Liss G.J. Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. Allergy Clin. Immunol. 2013, v. 131, р. 144-149.
- Гущин И.С. Полифункциональная противоаллергическая активность антигистаминного препарата рупатадина. Рос. Аллергол. Журн. 2012, № 4, с. 12-24.
- Martin Metz, Marcus Maurer. Rupatadine for the treatment of allergic rhinitis and urticaria. Expert Review of Clinical Immunology. 2011, v. 7, р. 15-20.
- Siebenhaar F., Fortsch A., Krause K. Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy. 2013, v. 68, р. 949-952.